• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vir Biotechnology Inc (NQ: VIR )

    7.690 +0.040 (+0.52%)
    Streaming Delayed Price Updated: 10:25 AM EDT, Sep 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Vir Biotechnology Inc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
    EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Exposures COVID-19
    Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    Breaking Down Vir Biotechnology: 6 Analysts Share Their Views
    Via Benzinga
    Evaluating Vir Biotechnology: Insights From 5 Financial Analysts
    Via Benzinga
    Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
    Via Benzinga
    Assessing Vir Biotechnology: Insights From 5 Financial Analysts
    Via Benzinga
    Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
    From FN Media Group LLC
    Via GlobeNewswire
    VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024
    VIR stock results show that Vir Biotechnology missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
    On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier. 
    Via Investor's Business Daily
    Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
    These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise. 
    Via InvestorPlace
    Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
    From Vir Biotechnology, Inc.
    Via Business Wire
    Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
    Vir Biotechnology reports promising Phase 2 SOLSTICE hepatitis delta trial results, showing high virologic response and ALT normalization rates with tobevibart and elebsiran. 
    Via Benzinga
    Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
    From Vir Biotechnology, Inc.
    Via Business Wire
    Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024
    VIR stock results show that Vir Biotechnology beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
    These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations. 
    Via InvestorPlace
    Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
    One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses. 
    Via InvestorPlace
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.